title: Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
authors: 1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
authors: Michael
authors: M
authors: DeGregorio
authors: 1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
authors: Lin
authors: L
authors: Soe
authors: 1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
authors: Michael
authors: M
authors: Wolf